Knowledge and provision practices of misoprostol among pharmacies in Senegal by Ndao, Ramatoulaye et al.
Population Council 
Knowledge Commons 
Reproductive Health Social and Behavioral Science Research (SBSR) 
2014 
Knowledge and provision practices of misoprostol among 








See next page for additional authors 
Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh 
 Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society 
Commons, Gender and Sexuality Commons, International Public Health Commons, Maternal and Child 
Health Commons, Pharmacy and Pharmaceutical Sciences Commons, and the Women's Health 
Commons 
Recommended Citation 
Ndao, Ramatoulaye, Babacar Mane, Eva Burke, Nafissatou Diop, Kate Reiss, Thoai Ngo, Katharine 
Footman, and Maaike Van Min. 2014. "Knowledge and provision practices of misoprostol among 
pharmacies in Senegal," STEP UP Research Report. Dakar: Marie Stopes International and Population 
Council. 
This Report is brought to you for free and open access by the Population Council. 
Authors 
Ramatoulaye Ndao, Babacar Mane, Eva Burke, Nafissatou Diop, Kate Reiss, Thoai Ngo, Katharine 
Footman, and Maaike Van Min 




Knowledge and provision practices 
of misoprostol among pharmacies 
in Senegal 
 
RAMATOULAYE NDAO, BABACAR MANE, EVA BURKE, NAFISSATOU DIOP, KATE REISS, 
THOAI NGO, KATHARINE FOOTMAN, MAAIKE VAN MIN  
 








Knowledge and provision 
practices of misoprostol among 
pharmacies in Senegal 
 
RAMATOULAYE NDAO1, BABACAR MANE2, EVA BURKE1, NAFISSATOU DIOP2, 
KATE REISS1, THOAI NGO1, KATHARINE FOOTMAN1, MAAIKE VAN MIN1 
1 Marie Stopes International 
2 Population Council  
 
















The STEP UP (Strengthening Evidence for Programming on Unintended Pregnancy) Research 
Programme Consortium generates policy-relevant research to promote an evidence-based approach for 
improving access to family planning and reducing unwanted pregnancies. STEP UP focuses its activities in 
five countries: Bangladesh, Ghana, India, Kenya, and Senegal. STEP UP is coordinated by the Population 
Council in partnership with the African Population and Health Research Center; ICDDR,B; the London 
School of Hygiene and Tropical Medicine; Marie Stopes International; and Partners in Population and 





Marie Stopes International (MSI) is a British non-profit organization that provides family planning and 
reproductive health services to millions of underprivileged and underserved men and women worldwide 
each year.  MSI is one of the largest organizations in the world to provide family planning services with a 





The Population Council confronts critical health and development issues—from stopping the spread of HIV 
to improving reproductive health and ensuring that young people lead full and productive lives. Through 
biomedical, social science, and public health research in 50 countries, they work with partners to deliver 
solutions that lead to more effective policies, programs, and technologies that improve lives around the 
world. Established in 1952 and headquartered in New York, the Council is a nongovernmental, non-profit 
organization governed by an international board of trustees. www.popcouncil.org 
 
Suggested citation: Ndao, R., Mane, B., Burke, E., Diop, N., Reiss, K., Ngo, T., Footman., K, van Min, M., 
2014, « Knowledge and provision practices of misoprostol among pharmacies in 
Senegal. STEP UP Research Report,” Dakar, Marie Stopes International & Population 
Council 
 
Please address any inquiries about STEP UP to the RPC co-directors:  
Dr. Harriet Birungi, hbirungi@popcouncil.org 












Table of Contents 
Acknowledgements ................................................................................................................................ i 
Executive Summary .............................................................................................................................. ii 
Introduction ........................................................................................................................................... iii 
Methodology .......................................................................................................................................... 2 
Results .................................................................................................................................................. 4 
Discussion and Recommendations ....................................................................................................... 9 
Limitations…………………………………………………………………………………………………………10 
Conclusions……………………………………………………………………………………………………….11 





The research team expresses its appreciation to all individuals and institutions who participated in the realization 
of this work.  This study could not have been conducted if they had not agreed to participate.  They should find 
here the expression of our gratitude.  The implementation of this study was made possible through funding from 
the STEP UP consortium.   
We thank Dr Bocar Mamadou Daff, Director of the Direction of Reproductive Health and Child Survival, Ministry 
of Health, for his commitment to this study since its inception.  We also thank the Order of Pharmacists, in 
particular its President Dr. Cheikhou Oumar Dia, who kindly gave us his time, shared his expertise with us, 
engaged pharmacists in this study and provided us with the list of pharmacies in Dakar.  Our thanks are also 
extended to the pharmacists who were willing to accommodate our research teams and to be interviewed.  All 








In developing countries, post-partum haemorrhage (PPH) and complications related to unsafe abortions are 
direct causes of maternal death. In Senegal, actions have been undertaken by the Government to reduce this 
burden and significant advances have been made in these areas in recent years. However, progress is still 
necessary to achieve the Millennium Development Goals (MDGs) for the reduction of the Maternal Mortality Rate 
(MMR) from 392 deaths per 100,000 live births in 2010–2011 to the target of 127 deaths per 100,000 live births 
by 2015.  Misoprostol, a synthetic prostaglandin medicine, is recognized as essential for the management of 
PPH and for post-abortion care (PAC), hence its inclusion on the List of Essential Medicines (LEM) of the World 
Health Organization (WHO) and of the Senegal Ministry of Health. Recent studies in Senegal showed high levels 
of efficacy and acceptability of misoprostol for PPH and PAC. 
Objectives 
The objective of the study was to understand the knowledge about, availability of and the practices in the 
provision of misoprostol at pharmacies in Dakar, Senegal, to ensure correct delivery of the product.  The results 
will guide strategies for provision of misoprostol and for the reduction of maternal morbidity and mortality.   
Methodology 
A Knowledge, Attitudes and Practices (KAP) survey was conducted among 110 pharmacists to gather 
information about misoprostol provision. Data were collected on: 1) availability of misoprostol; 2) pharmacists’ 
knowledge of misoprostol; and 3) reported misoprostol provision practices. 
Results 
A large proportion of pharmacists (72%) had heard of misoprostol, but there was low product availability, with 
only 34% of pharmacists selling misoprostol at the time of the study. Three brands were available: Cytotec, 
Misoclear and Arthrotec.  Few respondents reported selling misoprostol for gynaecological purposes, with most 
reporting that the product was sold primarily for gastric and duodenal ulcers (70%) and occasionally for PAC 
(3.7%); no pharmacist reported selling misoprostol for management of PPH (0%).  An average of 58 tablets was 
sold monthly by pharmacies. Almost half of pharmacists (48%) who are not currently selling the product 
expressed interest in doing so. 
Almost two-thirds (62%) of pharmacists who have heard of misoprostol have been trained in or informed about 
the product; most were self-taught. Knowledge about the registration status, gynaecological uses, dosage and 
route of administration, side effects and storage condition for misoprostol were low. Half of those surveyed did 
not feel comfortable providing misoprostol to women, and 85% of pharmacists would like to have more 
information and documentation on the product. 
Discussion and recommendations  
Despite little knowledge and provision of misoprostol by pharmacists, the majority have expressed a wish for 
training in order to put the product on the market in an adequate manner.  Training has shown some positive 
effects on product knowledge and improving pharmacists’ capacity to provide the product correctly. Demand for 
the sale of misoprostol exists, but pharmacies cannot provide the product without a prescription. Therefore, 
health care providers who can prescribe this product play an essential role that needs to be explored to better 
understand the reasons for the current low level of prescriptions and, consequently, sales.   
Senegal has committed itself to the fight against maternal morbidity and mortality, with commitments made at the 




important to strengthen strategies to reduce the disastrous consequences of PPH and complications linked to 
incomplete/ unsafe abortion.  This is reinforced by the presence of misoprostol on the LEM.  Pharmacists are the 
key intermediaries because they are an integral part of misoprostol provision to both individuals and health 
facilities.  Thus, it is imperative that they be involved in the national implementation plans for the availability, safe 
delivery, and scaling up of the product throughout the country.  
Introduction 
Over the past two decades, Senegal has made progress in reducing maternal mortality; however, improvement is 
still needed especially in regard to achieving the Millennium Development Goal (MDG) to reduce the Maternal 
Mortality Ratio (MMR).  In 2010-2011 DHS, the MMR was estimated at 392 per 100 000 live births. Senegal aims 
to reduce the rate to 127 deaths per 100 000 live births by 2015i. 
Major complications that contribute to maternal deaths are severe bleeding, infections, hypertension and unsafe 
abortionsii.  Maternal deaths most often occur during labour, delivery and during the immediate post-partum 
period, or following complications from an abortion.  In 2006, a systematic review showed that postpartum 
haemorrhage (PPH) caused more than 30% of maternal deaths worldwideiii.  In Senegal, it is estimated that PPH 
causes 25% of maternal deathsiv.  
Worldwide, 13% of maternal deaths are caused by complications linked to abortion. Senegal has a very 
restrictive abortion law; abortion is illegal except in the case of saving the woman’s life. In Senegal, available 
statistics show that 4% of maternal deaths are due to unsafe abortions, and for every 4 women who die following 
an abortion, 10 others are struck with illness or disabilityv.  These figures are probably a large underestimation 
because maternal deaths due to the disastrous consequences of illegal abortions often go unreported in official 
statistics. 
Misoprostol is a synthetic prostaglandin medicine which received approval for introduction in more than 85 
countries since its appearance on the market in 1985 for the prevention and treatment of gastric ulcers.  Because 
the medicine is an uterotonic, it causes the ripening of the cervix and uterine contractions.  It is therefore widely 
used in the prevention and the treatment of PPH and for post-abortion care (PAC).vi  It is also used for the 
treatment of intrauterine foetal death and cervical ripening during certain surgeries. In 2011, misoprostol was 
included in the 17th edition of the WHO’s List of Essential Medicines (LEM) for several gynaecological and 
obstetric uses, including the prevention of PPH when oxytocin is not available or cannot be used safely, for 
labour induction and PACvii. 
Since 2013, misoprostol has been on the LEM in Senegal as an anti-haemorrhagic and a haemostatic, and the 
product is available in the country for several uses including gastric ulcers, PAC and the prevention and 
treatment of PPH.  However, the current availability of the product is low, only 1% of public and private health 
facilities in Senegal have the product available.viii In 2014, the National Pharmacy of the Ministry of Health (MoH) 
launched a tender to buy misoprostol for the first time, but at the time of this report the product was not yet 
available for sale through the National Pharmacy.  
Research was conducted in Senegal to assess the effectiveness and acceptability of misoprostol for PPH and 
PAC.  In 2010, a study was conducted on the use of misoprostol in health huts in Senegal by the Ministry of 
Health in partnership with USAID, ABT/Associates and the Centre for Research and Training in Reproductive 
Health (CEFOREP).ix  It showed that misoprostol could be successfully administered by birth attendants (under 
supervision) in health huts for the prevention of PPH. The results also showed that administration of misoprostol 
soon after birth could reduce the risks of haemorrhaging and is practically the only means to control PPH. 
Moreover, because misoprostol does not require refrigeration and can be taken orally, administration is easier by 
providers at the community level.   
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In the same vein, ChildFund and Gynuity conducted a study in 2013 to understand the efficacy and acceptability 
of two products (oxytocin and misoprostol) for the prevention of PPH and the feasibility of their use without 
supervision in health huts by birth attendants trained to prevent PPH. The results showed a very high level of 
efficacy of misoprostol and total satisfaction (100%) with the product by the womenx.   
A recent study showed that of 481 women who went to health huts for treatment of incomplete abortions, 99.4% 
of them received effective PAC treatment with misoprostol and 99.6% were satisfied or very satisfied with the 
productxi. Misoprostol is therefore deemed effective and easy to administer for PAC including at the community 
level in Senegal.  Previously, PAC techniques were limited to dilation, curettage and manual or electric vacuum.  
Misoprostol offers an opportunity to avoid surgical procedures in resource poor environments because it is easy 
to store and administer.   
While it is important to ensure access to a high quality product and extend the geographical availability of 
misoprostol, it is as important to monitor and maintain the quality of services related to the practices of 
prescribers and sellers of misoprostol.  All the benefits of misoprostol cannot be achieved without complete 
knowledge of appropriate treatment, an understanding of laws pertaining to misoprostol provision and an 
understanding of the side effects and possible complications.   
Several studies have shown that pharmacies are the main resources for certain populations for services related 
to healthxii. Indeed, these represent an important source of information, advice and supply of medicine.  
Nevertheless, even if they cannot replace a health care provider, a pharmacist, an actor in the health field, can 
always advise or refer clients in order to meet their needs. Pharmacies are often more accessible to the 
population in regards to geographic location, opening hours, wait times and do not require any consulting fees.   
In Senegal, pharmacies are part of the supply system of pharmaceutical medicines, not only for individuals but 
also for health care providers.  Medical staff (midwives, nurses and doctors) in the public and private sectors can 
have access to medicines through pharmacies that buy and keep a stock of them.  There are approximately 900 
pharmacies in Senegal and 60% of these are in Dakar, in other words, 557 pharmacies.   
Although studies have been conducted in Senegal to assess the level of effectiveness and acceptability of 
misoprostol and its use in different contexts, there has not been any research or any documentation on 
knowledge and practices of misoprostol provision in pharmacies where the product is currently available and 
sold.  It is with this in mind that this study was conducted, with the objective to assess knowledge, availability and 
practices of misoprostol provision in pharmacies in Dakar.  The results will inform strategies aimed at reducing 
maternal morbidity and mortality, inform and guide the strategies of product distribution, necessary trainings, 
awareness campaigns for providers as well as pharmacists and the implementation or strengthening of reference 




Type of study 
A survey of Knowledge, Attitudes and Practices (KAP) was conducted among a sample of pharmacists in Dakar.   
Ethical considerations 
Before the start of the study, ethical approval was obtained from three sources:  
The Institutional Review Board (IRB) of Population Council  
The Ethics Review Committee of Marie Stopes International 
The National Ethics Committee for Health Research in Senegal  
 
Informed consent forms were submitted to pharmacists to gather their consent before their enrolment in the 




The study population consisted of pharmacy owners, managers or staff members working in selected 
pharmacies and who are involved in the sale of medicines.  110 pharmacies were randomly selected from the list 
of 557 pharmacies that are in the four districts of Dakar and divided into the following areas: Dakar, Pikine, 
Guédiawaye, and Rufisque. The final number of pharmacies per district was proportional to the number of 
pharmacies in each of these areas.   
Sample size calculation was based on a 95% confidence interval within 10 percentage points. Using the formula 
for precision of a single proportion: 
Sample size (n) = (z/m) 2 * π (1- π) 
 
 Where:   π = proportion (0.5) 
m = margin of error (0.1) 
z = 95% CI (1.96) 
 
We estimated that a minimum sample size of 96 is required. We increased this to 110 to allow for non-response.  
 
Recruitment and data collection procedures  
The Order of Pharmacists’ involvement was essential since project inception. In particular, they provided the list 
of pharmacies in Dakar and addressed Information Letters to pharmacy managers prior to data collection. 
Data collectors with social science research experience were trained in interview techniques and in completing 
questionnaires by a joint team from Population Council and MSI.   
A standardized, structured questionnaire was developed for data collection. The questionnaire collected 
information on characteristics of the pharmacy, the pharmacy’s staff, knowledge and practices of pharmacy staff 
around misoprostol availability, and also included questions regarding the frequency of misoprostol sales.   
The questionnaire was pre-tested in eight pharmacies in Dakar. Three pharmacies were assigned to each of the 
data collectors with an objective to deliver at least two completed questionnaires. This objective was achieved. 
The research team provided technical oversight of the pre-test phase. A debriefing session was held with the 
data collectors to discuss the challenges encountered and how best to overcome them.  
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In the selected pharmacies, the owner or the manager was initially invited to answer the questionnaire if he/she 
met the following criteria:  
 The respondent gave informed consent to participate in the study.   
 The respondent was 18 years of age or older.   
 The respondent was involved in the sale/distribution of medicines.   
If neither the owner nor the manager met the criteria (for example if neither distributed medicines), the 
questionnaire was administered to the most senior employee responsible for selling medicines.  This choice was 
made because a more junior employee would be more likely to refer a client to a more senior staff member when 
a client asks questions about products about which their knowledge was insufficient. One employee was 
interviewed per pharmacy. Data collection took place in September 2013.  
Data processing and analysis  
Two experienced operators performed a double data entry using Epi Info 3.5.4. A dictionary of variables was 
developed to document the data correctly.  Data were thereafter transferred into STATA version 12. Descriptive 
analyses were done to interpret the demographic data (age, education, training, etc.).  Bivariate analyses were 
done according to thematic groups such as: ‘Information on the pharmacies’, ‘Knowledge and practices of the 
pharmacies’ and ‘Information on misoprostol’.   
Qualitative data were transcribed and converted into text files for formatting.  Thematic analysis was done 
through the content analysis.   
Key study indicators 
The key indicators for data collection were the following: 
Indicator 
a. Availability of misoprostol  
Number/percentage of outlets who sell misoprostol to health providers 
Number/percentage of outlets who sell misoprostol to end users 
Brands of misoprostol that are available 
Average cost of 200mcg misoprostol or box of misoprostol  
b. Knowledge of misoprostol 
Number/percentage of pharmacy staff who know an effective regimen prevention/treatment 
of gastric ulcers 
Number/percentage of pharmacy staff who know an effective regimen for PPH 
treatment/prevention 
Number/percentage of pharmacy staff who know an effective regimen for PAC 
Number/percentage of pharmacy staff who can list 4 or more possible side effects of 
misoprostol 
Number/percentage of pharmacy staff who can list possible complications of misoprostol 
treatment for PAC 
Number/proportion of pharmacy staff that express a need for further training / information on 
misoprostol 
c. Reported Misoprostol provision practices 
Quantity of misoprostol sold / outlet / month 
Number/proportion of pharmacies that sell misoprostol to end users for gastric ulcers 
Number/proportion of pharmacies that sell misoprostol to end users for PPH 




Almost three-quarters (72%) of the respondents had heard of misoprostol. The findings from these respondents 
only are presented below. 
Demographics of respondents 
Employees and owners were the most represented in the sample, 41% and 43% respectively. Fewer managers 
were interviewed.  The majority of pharmacists were aged between 31 and 50 years old, with 53% under 40.  
The level of education was high with 77% having a university education and 23% secondary level education; 
none had only primary level education.  In terms of training for the position held in the facility, 73% have received 
training in a university and 19% have completed training in the private sector, with 6% trained on-site.  Higher 
levels of formal training were found in the department of Dakar, with higher proportions in Pikine, Guédiawaye 
and Rufisque having received on-the-job training. 
Knowledge of Misoprostol 
Several misoprostol brands are registered in the country for multiple uses: the treatment of duodenal and gastric 
ulcers or ulcers caused by taking non-steroidal anti-inflammatory drugs (NSAIDs), the prophylaxis of gastric 
ulcers caused by NSAID ulcers, the prevention of PPH, the treatment of PPH, PAC, the treatment of intrauterine 
foetal death and cervical ripening. 
However, the study found that many pharmacists were not aware of all the legal uses of misoprostol in Senegal 
(see table 1). The most commonly reported known use for misoprostol was the treatment of gastric ulcers, and 
only 61% knew it was registered for this use.  Only 13% of respondents knew that misoprostol is registered for 
use for PAC, yet 38% were aware that it can be used to induce an abortion and 6% wrongly though it is 
registered for this use. Knowledge of indications for other gynaecological uses such as cervical ripening (3%) 
and the treatment of intrauterine foetal deaths (2%) was extremely low.  Knowledge of the use and registration of 
misoprostol for PPH was also very low: only 4% of pharmacists knew of its use for the treatment of PPH and 1% 
for the prevention of PPH, and only 3% knew that misoprostol is registered for that use in Senegal. 
Table 1: Knowledge of uses for which misoprostol is registered 
Knowledge of indications        Used for  Registered for 
  n % n % 
Duodenal or gastric ulcer 59 75% 48 61% 
Post abortion care 10 13% 10 13% 
Prophylaxis of NSAID-induced peptic ulcers 5 6% 4 5% 
Treatment of PPH 3 4% 2 3% 
Prevention of PPH 1 1% 1 1% 
Cervical ripening 2 3% 1 1% 
Treatment for intrauterine foetal death 1 1% 0 0% 
 
Information and training on misoprostol  
62% of pharmacists reported having been trained or having received information on misoprostol.  Self-training 
was the most commonly cited method, including through literature/brochures. Other pharmacists and medical 
delegates also played a role. Although rarely cited, other sources of information included doctors, university, 




Table 2: Information sources and training (N=56) 
Information sources/training  
                       
n*  (%) 
Literature/Brochures 22 (45) 
Medical delegates  11 (22) 
Colleagues  10 (20) 
University 5 (10) 
Doctors 4 (8) 
Clients 2 (4) 
Television 1 (2) 
Internet 1 (2) 
NGO 0 (0) 
*amongst those who had heard of misoprostol  
 
Misoprostol storage conditions  
Knowledge of the storage conditions of a medicine is essential to ensure the effectiveness of a product.  
Although it does not require complex storage conditions, misoprostol should still be kept away from heat and 
moisture. However, many respondents were not aware of both storage conditions (Table 3). Trained pharmacists 
had better knowledge about humidity but not for heat. 
Table 3: Knowledge around storage conditions according to level of training  
 
Trained /Informed 
Not informed / 
Not trained 
Total 
Storage conditions  n % n % n % 
Keep away from heat  41 84 25 83 66 84 
Keep away from humidity  19 39 3 10 22 28 
 
Misoprostol side effects  
Knowledge of side effects of a medicine is important because it allows users to manage potential complications 
and to reassure themselves about the effectiveness of the medicine.  Among trained and informed providers, 
37% said that they did not know any side effects of misoprostol, whereas among untrained and/or uninformed 
pharmacists this figure reached 63%. Only 8 trained or informed pharmacists could name two side effects. The 
distribution by product training showed that trained or informed pharmacists were more able to name, in 










Table 4: Knowledge of side effects by training or information on product 
 
Trained/Informed            Untrained /Informed             Total 




Don’t know 18 37 19 63.3 37 46.8 
Dizziness 10 20 1 3.3 11 13.9 
Bleeding 4 8 2 6.7 10 12.7 
Diarrhoea 2 4 4 13 6 7.6 
Weakness 4 8 1 3.3 5 6.3 
Nausea 3 6 1 3 4 5.1 
Fever 2 4 1 3 3 3.8 
Headaches 3 6 0 0.0 3 3.8 
a Multiple responses could be provided   
 
Misoprostol dosages and administration  
Knowledge of the administration of a medicine is essential since it for proper usage by the client and to ensure its 
true efficacy. The results showed varying degrees of knowledge depending on its use.  Of the 30 pharmacists 
who said that they knew correct dosages for gastric and duodenal ulcers, 25 actually gave the proper dosage 
(83%).  In regards to PAC, of the 11 who stated that they knew the correct dosages, only three gave the correct 
answer.  For PPH, none of the pharmacists interviewed knew the correct dosages for either prevention or 
treatment (see Table 5). 
Table 5: Knowledge of correct dosages of misoprostol for certain indications  
Indication Correct dosage  % of pharmacists that 
said they know the 
correct dosage for the 
indication (n=79) 
% of respondents who 
gave the correct dosage  
(of those who claimed 
knowing correct dosage)  
Treatment of gastric ulcers  800mcg 38% 83% 
Treatment of PPH 800mcg 0% 0% 
Prevention of PPH 600mcg 0% 0% 
Post abortion care  400mcg to 600mcg* 14% 4% 
*dosage depends on if taken orally or sublingually  
 
 
Product information and training needs  
 
One fifth (21%) of pharmacists reported that health care providers solicit information on misoprostol from them, 
especially midwives (75%), gynaecologists (42%), nurses (33%) and general practitioners (17%).  The type of 
information solicited was not systematically explored during the interview. Pharmacies receive approximately 4 
visits per month from health care providers.  
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85% of pharmacists expressed a need for support and training in misoprostol.  In addition, 51% of respondents 
reported not being confident in regards to misoprostol provision to users.  Over half (58%) expressed a desire for 
training on all aspects of misoprostol provision; training needs around specific aspects of the product (uses, side 
effects, complications) are described in Table 6. 
 
Table 6: Themes for which there a training demand expressed  
Themes for which there is training demand  n   % 
All aspects of the product 39 (58) 
Misoprostol uses 25 (37) 
Side effects 20 (30) 
Dosage 19 (28) 
Complications 14 (30) 
Administration 5 (8) 
Storage conditions 2 (3) 
 
Misoprostol brands available on the market 
Several brands of misoprostol exist in the market in Senegal: 1) Cytotec was registered for the treatment of 
gastric ulcers; 2) Misoclear was registered in 2011 for additional gynaecological uses, including PAC and PPH; 
and 3) Arthrotec a combination medicine with diclofenac for the treatment of gastric ulcers. Table 7 shows that 
one third or 27 of the pharmacies sell misoprostol, with Arthrotec (56%) being the most commonly sold brand. 
The three products are sold in different packaging boxes with 60 tablets for Cytotec, 20 or 30 tablets for Arthrotec 
and 10 tablets for Misoclear which explains the variation in price per box.   
According to pharmacists, the choice of brands sold in pharmacies is justified by two main points: the efficacy of 
the product and its availability.  Compared to the ease of supply, all pharmacists stated that Arthrotec was the 
easiest to obtain, compared to 82% who said the same for Cytotec and 40% for Misoclear.    
Table 6: Misoprostol sales by brand and price  
Pharmacies who sell misoprostol*          n         (%)   
 
      
            
27            
(34) 
   
Brands sold  Dose  
Number of doses 
per box 
  n      (%) 
       Average 
price per box 
(FCFA)    
Average price 
per pill  
(FCFA) 
Arthrotec 200mcg 30 15 (56) 5,701      190  
       
Cytotec 200mcg 60 11 (41) 16,376      273  
       






Among pharmacists who have heard of misoprostol, only 34% actually sold it.  The product was most often sold 
per box according to 41% of pharmacists.  An average of 58 tablets of 200mcg of misoprostol was sold per 
month in each pharmacy.  However, 19% said that the sale depended on the quantity specified on the 
prescription. The product was sold primarily to treat duodenal and gastric ulcers (63%).  The prophylaxis of 
gastro duodenal induced by NSAIDs accounted for 7% of sales.  Demand for gynaecological uses including PPH 
and PAC was negligible.  22% of pharmacists stated that clients asked for the product without a prescription, and 
most often for gastric ulcers.  However, only 1 pharmacist reported selling it without a prescription.   
78% of pharmacists believed that all customers were able to pay the price compared to 11% who said that 
customers cannot afford it.    
The profile of customers who buy misoprostol was quite diversified: married men and women were the main 
customers. However, health care providers were also cited: doctors (19%), midwives (7%) and nurses (4%).   
Pharmacies that do not sell misoprostol 
Among pharmacists who have heard of misoprostol, 66% were not selling it at the time of the study. Graph 1 
below shows the diverse reasons that explain this fact. In addition, pharmacists claimed this situation resulted 
from the lack of demand for misoprostol (56%), stock-outs (46%) and not wanting to sell products that they 
consider to be abortifacient (42%).  The lack of knowledge of the law and of misoprostol supply chains were 
other barriers cited. Nearly half (48%) of pharmacists who did not sell the product stated that they wanted to do 
so, since they see customers who ask for it. 
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Discussion and Recommendations  
The pharmacist’s role is vital for the health of the general population.  As a contact point for the public, it is 
important that the pharmacist should have a good understanding of and a proper supply of misoprostol.  This 
study allows for a number of conclusions and recommendations.  They can be classified as follows. 
Knowledge of use for which misoprostol is registered in the country: These uses are known piecemeal.  
Although many pharmacists who have heard of the product know that it is registered for gastric and duodenal 
ulcers, few know that it also has approval for PPH and PAC. Historically, Cytotec has been available in the 
country for gastric ulcers and it was not until 2011 that a new product, Misoclear, was registered for additional 
gynaecological indications. Lack of knowledge of the status of registration of misoprostol for gynaecological 
indications could be explained by the lack of diffusion of this information on the new product with a different 
status of registration. Information on new medicines in the market and changes of registration status of existing 
products must be communicated to pharmacies by the Pharmacy and Medicine Division, especially those that 
are considered essential medicines. Effective and timely communication, as well as wide diffusion of the List of 
Essential Medicines within the health sector, is essential for making misoprostol more accessible on the market. 
The lack of knowledge of the legal indications for the use of misoprostol could have an effect on the perception 
pharmacists have of the product, and could affect their willingness and ability to sell it.   
Knowledge of the product and its therapeutic indications: Pharmacists know the product particularly as a 
medicine for gastric ulcers and PAC.  A very small proportion knows other indications such as prophylaxis for 
gastro duodenal ulcers induced by NSAIDs, and treatment and prevention of PPH. This lack of knowledge of its 
range of uses can be explained by the history of the product in the country; before 2011, misoprostol was not 
registered for gynaecological uses. In addition, the role of pharmacies in the supply of the product for 
gynaecological uses was low because most cases of PAC, PPH, and intrauterine foetal death are handled 
directly at health facilities. Additional studies are needed to explore how to develop stronger connections 
between service provision at health facility level and purchases at pharmacy level.  
To date, the essential medicines list has not been officially disseminated by the Ministry of Health in the country. 
Diffusion of this list will contribute to positioning misoprostol as an essential product and clarify the indications it 
can legally be used for, as well as help de-stigmatizing the product as an abortifacient.  
Knowledge of correct dosage: Knowledge of correct dosages varies according to use of the product.  
Knowledge of dosage for gastric or duodenal ulcers is relatively high, whereas very few know the proper 
dosages for PAC. No pharmacist was aware of the dosages for other uses of misoprostol, including PPH. 
This leaves a gap between the number providing the product and the number who know its correct dosages. The 
product is sold on prescription which will define the dosage but a pharmacist should know the correct dosages, 
especially given the nature of a medicine that can have adverse side effects if taken in the wrong dosage.  
Knowledge of side effects: Knowledge of side effects remains low and almost half of pharmacists could not 
name any.  However, some side effects are better known than others.  Communication on these side effects is an 
important step in product availability in order to ensure understanding of the possible effects users should expect 
and which ones require additional monitoring.   
Storage and storage conditions: Compliance with the storage conditions is important for the effectiveness of 
misoprostol.  The majority of pharmacists are aware that the product must be kept away from heat, but few are 
aware of the need to keep it away from moisture.   
Misoprostol training: Complete and adequate knowledge of all aspects of the product is essential to ensure 
proper provision of misoprostol which is an essential medicine that helps to save lives. The study reveals the 
potentially positive impact of training and information on product knowledge: those who are trained or informed 
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about the product had a better understanding of protecting against humidity during storage and knew the side 
effects better than those who had had no such training or information.  
Training needs were expressed for gynaecological uses of the product, especially for PAC and PPH; the majority 
of pharmacists who have heard of misoprostol expressed the wish for more information on all aspects of 
misoprostol use. The lack of confidence to provide misoprostol may be due in part to lack of training.  It is 
therefore important to put into place training sessions for pharmaceutical staff in order to overcome this lack of 
knowledge around the uses for which this product is registered in Senegal and to ensure correct knowledge of 
administration, storage and management of side effects.   
Following a presentation of the key findings of this study, the Ministry of Health committed to working with the 
Order and Syndicate of Pharmacists before the end of 2014 to ensure that essential medicines, including 
misoprostol, are made available in pharmacies and that pharmacists are trained on how to safely sell this 
essential product.  
Availability of misoprostol in pharmacies: Only 34% of pharmacists who knew of the product were selling 
misoprostol at the time of the study. This is fairly low for a product deemed essential in the fight against maternal 
mortality and which has been, moreover, registered since 2011 for new uses, amongst others PAC and the 
treatment and the prevention of PPH. 
Three brands are currently available in Senegal: Arthrotec, Cytotec and Misoclear.  These brands differ in the 
indications for which they are registered, the packaging and the sale price.  According to pharmacists, the 
product price is relatively affordable and does not constitute a barrier to its acquisition by users.  For pharmacies 
that sell misoprostol it is mainly for uses linked to gastric ulcers.  
This research has also shown that a negligible number of sales of misoprostol are without a prescription.  
It should be noted as well that health care providers come to the pharmacy not only to get information, but also to 
buy misoprostol, especially those who work in reproductive health such as midwives and gynaecologists. Indeed, 
at the moment, misoprostol cannot be purchased in the public sector. Therefore, health providers from all sectors 
must purchase it or prescribe for purchase at a pharmacy level. When the product becomes available in the 
public sector, there will still be a demand for the product from private sector facilities that cannot access public 
products.   
Some pharmacists argue that demand for misoprostol is low and this explains why they do not stock it or sell 
large quantities. However, low sales are clearly a direct result of low levels of use or prescription for the product 
by health providers. Nevertheless, it is encouraging that almost half of pharmacies who are not stocking and 
selling misoprostol at the time of the study expressed a desire to do so. As the product therapeutic indications 
and LEM status become better known by health providers, prescriptions will increase. It will be important that the 
supply chain and the pharmacies ensure product availability consistently and in sufficient quantity. 
Limitations 
This is the first study in Senegal to focus on the knowledge and practices of misoprostol provision in pharmacies.  
There were some methodological limitations.  Since misoprostol can be used as an abortifacient product and 
because of the restrictive context in the country around abortion, there may have been some denial on the part of 
pharmacists and biases in their responses. Responses to questions about the availability of misoprostol for 
gynaecological uses (for example, managing references to health facilities) were not presented because the 
number of such responses was very low.  Moreover, limiting the study to Dakar prevents information on 





The study results indicate that knowledge of pharmacy personnel around misoprostol needs to be strengthened 
to enable them to play a more effective role in providing the product for gynaecological uses and in minimizing 
misperceptions. The Senegalese government has made significant efforts in the fight against maternal mortality. 
Misoprostol is now on the LEM, but this list remains to be widely disseminated, which undervalues the 
importance of, and the government’s recognition of, this essential product. However, in view of the role and place 
of pharmacies in the provision of health care services, it is still necessary to ensure good availability of 
misoprostol in pharmacies to help Senegal tackle the burdens of PPH and the disastrous consequences of 
unsafe and incomplete abortions.  This will also be in line with the fact that the Senegalese government adopted 
recommendations at the dissemination meeting in January 2014 of studies conducted by ChildFund and Gynuity 
that advocated for the scaling up of misoprostol availability to prevent PPH at a community-level. This study did 
not address availability in pharmacies but in order to scale up product availability, the pharmacies play a critical 
role whilst the product remains unavailable in the public health sector.  
At the time of writing, misoprostol was not available in the public health system. With the on-going need for the 
product for public providers, and long-term need for all private sector providers, pharmacies play an essential 
role today for enabling access to misoprostol in the country and at health facilities at all levels of the health 
pyramid. As demand for the product will increase, the supply chain must be strengthened to respond effectively 
and avoid shortages.  
The Ministry of Health has committed to working with the Order and Syndicate of Pharmacies to ensure the 
availability of essential medicines, including misoprostol, and that pharmacists are trained in all aspects that 
allow them to safely sell misoprostol for gynaecological purposes. This commitment must be upheld to contribute 
to reducing the MMR and reaching national goals. Misoprostol has a significant role to play, but it must be made 
more available where people actually will get it from i.e. the pharmacies.  
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